Search

Your search keyword '"Laack, Nadia N."' showing total 646 results
Start Over Author "Laack, Nadia N."
646 results on '"Laack, Nadia N."'

2. Evolution of Proton Radiation Therapy Brainstem Constraints on the Pediatric Proton/Photon Consortium Registry

Author

Correia, Dora, Indelicato, Daniel J., Paulino, Arnold C., Ermoian, Ralph, Mihalcik, Stephen, Perkins, Stephanie M., Hill-Kayser, Christine, Mangona, Victor S., Lee, Jae, Chang, John Han-Chih, Laack, Nadia N., Kwok, Young, Perentesis, John, Vatner, Ralph, Dave, Ronak, Gallotto, Sara L., Lawell, Miranda P., Bajaj, Benjamin V.M., Allison, Keith W., Perry, Alisa, and Yock, Torunn I.

Published
2024
Full Text
View/download PDF

4. Impact of Apolipoprotein E Genotype on Neurocognitive Function in Patients With Brain Metastases: An Analysis of NRG Oncology's RTOG 0614

Author

Wefel, Jeffrey S., Deshmukh, Snehal, Brown, Paul D., Grosshans, David R., Sulman, Erik P., Cerhan, Jane H., Mehta, Minesh P., Khuntia, Deepak, Shi, Wenyin, Mishra, Mark V., Suh, John H., Laack, Nadia N., Chen, Yuhchyau, Curtis, Amarinthia (Amy), Laba, Joanna M., Elsayed, Ahmed, Thakrar, Anu, Pugh, Stephanie L., and Bruner, Deborah W.

Published
2024
Full Text
View/download PDF

5. Assessment of minimum target dose as a predictor of local failure after spine SBRT

Author

Kowalchuk, Roman O., Mullikin, Trey C., Spears, Grant M., Johnson-Tesch, Benjamin A., Rose, Peter S., Siontis, Brittany L., Kun Kim, Dong, Costello, Brian A., Morris, Jonathan M., Gao, Robert W., Shiraishi, Satomi, Lucido, John J., Olivier, Kenneth R., Owen, Dawn, Stish, Bradley J., Waddle, Mark R., Laack, Nadia N., Park, Sean S., Brown, Paul D., and Merrell, Kenneth W.

Published
2024
Full Text
View/download PDF

7. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report

Author

Leavey, Patrick J, Laack, Nadia N, Krailo, Mark D, Buxton, Allen, Randall, R Lor, DuBois, Steven G, Reed, Damon R, Grier, Holcombe E, Hawkins, Douglas S, Pawel, Bruce, Nadel, Helen, Womer, Richard B, Letson, G Douglas, Bernstein, Mark, Brown, Kenneth, Maciej, Alexis, Chuba, Paul, Ahmed, Atif A, Indelicato, Daniel J, Wang, Dian, Marina, Neyssa, Gorlick, Richard, Janeway, Katherine A, and Mascarenhas, Leo

Subjects
Pediatric Cancer, Clinical Trials and Supportive Activities, Cancer, Pediatric Research Initiative, Pediatric, Clinical Research, Rare Diseases, Orphan Drug, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Cyclophosphamide, Female, Humans, Infant, Infant, Newborn, Male, Sarcoma, Ewing, Topotecan, Vincristine, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe primary aim of this phase III randomized trial was to test whether the addition of vincristine, topotecan, and cyclophosphamide (VTC) to interval compressed chemotherapy improved survival outcomes for patients with previously untreated nonmetastatic Ewing sarcoma.MethodsPatients were randomly assigned to receive standard five-drug interval compressed chemotherapy (regimen A) for 17 cycles or experimental therapy with five cycles of VTC within the 17 cycles (regimen B). Patients were stratified by age at diagnosis (< 18 years and ≥18 years) and tumor site (pelvic bone, nonpelvic bone, and extraosseous). Tumor volume at diagnosis was categorized as < 200 mL or ≥ 200 mL. Local control occurred following six cycles. Histologic response was categorized as no viable or any viable tumor. Event-free survival (EFS) and overall survival (OS) were compared between randomized groups with stratified log-rank tests.ResultsOf 642 enrolled patients, 309 eligible patients received standard and 320 received experimental therapy. The 5-year EFS and OS were 78% and 87%, respectively. There was no difference in survival outcomes between randomized groups (5-year EFS regimen A v regimen B, 78% v 79%; P = .192; 5-year OS 86% v 88%; P = .159). Age and primary site did not affect the risk of an EFS event. However, age ≥ 18 years was associated with an increased risk of death at 5 years (hazard ratio 1.84; 95% CI, 1.15 to 2.96; P = .009). The 5-year EFS rates for patients with pelvic, nonpelvic bone, and extraosseous primary tumors were 75%, 78%, and 85%, respectively. Tumor volume ≥ 200 mL was significantly associated with lower EFS.ConclusionWhile VTC added to five-drug interval compressed chemotherapy did not improve survival, these outcomes represent the best survival estimates to date for patients with previously untreated nonmetastatic Ewing sarcoma.

Published
2021

9. Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma

Author

Fleming, Jessica L, Pugh, Stephanie L, Fisher, Barbara J, Lesser, Glenn J, Macdonald, David R, Bell, Erica H, McElroy, Joseph P, Becker, Aline P, Timmers, Cynthia D, Aldape, Kenneth D, Rogers, C Leland, Doyle, Thomas J, Werner-Wasik, Maria, Bahary, Jean-Paul, Yu, Hsiang-Hsuan Michael, D'Souza, David P, Laack, Nadia N, Sneed, Penny K, Kwok, Young, Won, Minhee, Mehta, Minesh P, and Chakravarti, Arnab

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Clinical Research, Genetics, Brain Cancer, Brain Disorders, Cancer, Brain Neoplasms, DNA Methylation, DNA Modification Methylases, DNA Repair Enzymes, DNA-Binding Proteins, Genomics, Glioma, Humans, RNA-Binding Proteins, Temozolomide, Tumor Suppressor Proteins, Oncology and carcinogenesis
Abstract

PurposeThis study sought to determine the prognostic significance of the WHO-defined glioma molecular subgroups along with additional alterations, including MGMT promoter methylation and mutations in ATRX, CIC, FUBP1, TERT, and TP53, in NRG/RTOG 0424 using long-term follow-up data.MethodsMutations were determined using an Ion Torrent sequencing panel. 1p/19q co-deletion and MGMT promoter methylation were determined by Affymetrix OncoScan and Illumina 450K arrays. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and tested using the log-rank test. Hazard ratios were calculated using the Cox proportional hazard model. Multivariable analyses (MVAs) included patient pretreatment characteristics.ResultsWe obtained complete molecular data to categorize 80/129 eligible patients within the WHO subgroups. Of these, 26 (32.5%) were IDHmutant/co-deleted, 28 (35%) were IDHmutant/non-co-deleted, and 26 (32.5%) were IDHwild-type. Upon single-marker MVA, both IDHmutant subgroups were associated with significantly better OS and PFS (P values < .001), compared with the IDHwild-type subgroup. MGMT promoter methylation was obtained on 76 patients, where 58 (76%) were methylated and 18 (24%) were unmethylated. Single-marker MVAs demonstrated that MGMT promoter methylation was statistically significant for OS (P value < .001) and PFS (P value = .003). In a multimarker MVA, one WHO subgroup comparison (IDHmutant/co-deleted v IDHwild-type) was significant for OS (P value = .045), whereas MGMT methylation did not retain significance.ConclusionThis study reports the long-term prognostic effect of the WHO molecular subgroups, MGMT promoter methylation, and other mutations in NRG/RTOG 0424. These results demonstrate that the WHO molecular classification and MGMT both serve as strong prognostic indicators, but that MGMT does not appear to add statistically significant prognostic value to the WHO subgrouping, above and beyond IDH and 1p/19q status.

Published
2021

10. Extent of Surgical Resection as a Predictor of Tumor Progression in Skull Base Chordomas: A Multicenter Volumetric Analysis

Author

Perez-Vega, Carlos, Akinduro, Oluwaseun O., Ruiz-Garcia, Henry J., Ghaith, Abdul Karim A., Almeida, Joao P., Jentoft, Mark E., Mahajan, Anita, Janus, Jeffrey R., Bendok, Bernard R., Choby, Garret W., Middlebrooks, Erik H., Trifiletti, Daniel M., Chaichana, Kaisorn L., Laack, Nadia N., Quinones-Hinojosa, Alfredo, and Van Gompel, Jamie J.

Published
2024
Full Text
View/download PDF

15. Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline

Author

Halasz, Lia M., Attia, Albert, Bradfield, Lisa, Brat, Daniel J., Kirkpatrick, John P., Laack, Nadia N., Lalani, Nafisha, Lebow, Emily S., Liu, Arthur K., Niemeier, Heather M., Palmer, Joshua D., Peters, Katherine B., Sheehan, Jason, Thomas, Reena P., Vora, Sujay A., Wahl, Daniel R., Weiss, Stephanie E., Yeboa, D. Nana, Zhong, Jim, and Shih, Helen A.

Published
2022
Full Text
View/download PDF

16. Development and Internal Validation of a Recursive Partitioning Analysis–Based Model Predictive of Pain Flare Incidence After Spine Stereotactic Body Radiation Therapy

Author

Kowalchuk, Roman O., Mullikin, Trey C., Harmsen, William S., Rose, Peter S., Siontis, Brittany L., Kim, Dong Kun, Costello, Brian A., Morris, Jonathan M., Marion, Joseph T., Johnson-Tesch, Benjamin A., Gao, Robert W., Shiraishi, Satomi, Lucido, John J., Olivier, Kenneth R., Owen, Dawn, Stish, Bradley J., Laack, Nadia N., Park, Sean S., Brown, Paul D., and Merrell, Kenneth W.

Published
2022
Full Text
View/download PDF

19. Establishing the minimal clinically important difference of the Brief Fatigue Inventory for brain or CNS cancer patients undergoing radiotherapy.

Author

Gunn, Heather J, Zaniletti, Isabella, Breen, William G, Leavitt, Todd, Bogan, Aaron, Mahajan, Anita, Brown, Paul D, Yan, Elizabeth, Vora, Sujay A, Merrell, Kenneth W, Ashman, Jonathan B, Peterson, Jennifer L, Leenstra, James L, Wilson, Zachary C, Laughlin, Brady S, Laack, Nadia N, and DeWees, Todd A

Subjects
MENTAL fatigue, BRAIN cancer, FATIGUE (Physiology), END of treatment, MEASUREMENT errors
Abstract

Background Minimal clinically important differences (MCIDs) quantify the clinical relevance of quality of life results at the individual patient and group level. The aim of this study was to estimate the MCID for the Brief Fatigue Inventory (BFI) and the Worst and Usual Fatigue items in patients with brain or CNS cancer undergoing curative radiotherapy. Methods Data from a multi-site prospective registry was used. The MCID was calculated using distribution-based and anchor-based approaches. For the anchor-based approach, the fatigue item from the PROMIS-10 served as the anchor to determine if a patient improved, deteriorated, or had no change from baseline to end of treatment (EOT). We compared the unadjusted means on the BFI for the 3 groups to calculate the MCID. For the distribution-based approaches, we calculated the MCID as 0.5 SD of the scores and as 1.96 times the standard error of measurement. Results Three-hundred and fifty nine patients with brain or CNS tumors undergoing curative radiotherapy filled out the 9-item BFI at baseline and EOT. The MCID for the BFI was 1.33 (ranging from 0.99 to 1.70 across the approaches), 1.51 (ranging from 1.16 to 2.02) and 1.76 (ranging from 1.38 to 2.14) for the usual and worst fatigue items, respectively. Conclusions This study provides the MCID ranges for the BFI and Worst and Usual fatigue items, which will allow clinically meaningful conclusions to be drawn from BFI scores. These results can be used to select optimal treatments for patients with brain or CNS cancer or to interpret BFI scores from clinical trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Survivorship care planning in neuro-oncology.

Author

Leeper, Heather E, Acquaye, Alvina A, Bell, Susan, Clarke, Jennifer L, Forst, Deborah, Laack, Nadia N, Link, Michael J, Taylor, Jennie W, and Armstrong, Terri S

Subjects
Neuro-oncology, patient care planning, survivorship care planning, Clinical Research, Hematology, Cancer, Rare Diseases, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being
Abstract

Cancer patient survivorship has become a significant topic within oncology care for both adult and pediatric patients. Starting in 2005, the Institute of Medicine recommended the use of survivorship care plans to assist patients transitioning from active treatment to the posttreatment phase of their cancer care, a critical time for many patients. Since 2014 there has been a mandate within the United States for adult cancer patients treated with curative intent to receive survivorship care plans comprised of a treatment summary and a follow-up plan to facilitate a better understanding among patients of what to expect after treatment. In addition to a general oncology survivorship care plan, specific care plans have been created for breast, lung, prostate, and colon cancers, as well as lymphoma. A survivorship care plan specific to adult neuro-oncology has been developed by a multidisciplinary and interprofessional committee, with approval from the Society for Neuro-Oncology Guidelines Committee. It has been published in compendium with this review of survivorship care planning and available as a fillable PDF on the Society of Neuro-Oncology Guidelines Endorsement web page (https://www.soc-neuro-onc.org/SNO/Resources/Survivorship_Care_Plan.aspx). Implementation of this survivorship care plan provides a unique opportunity to begin addressing the range of survivorship issues our neuro-oncology patients navigate from diagnosis to end of life.

Published
2018

24. Outcomes of patients with stage I–II Hodgkin lymphoma who had uniform pre-treatment staging with PET/CT and treatment with limited field radiation therapy after chemotherapy

Author

Frechette, Kelsey M., Lester, Scott C., Taparra, Kekoa, Breen, William G., Martenson, James A., Hoppe, Bradford S., Peterson, Jennifer L., Rule, William G., Stafford, Scott L., Stish, Bradley J., Habermann, Thomas M., Young, Jason R., Harmsen, William S., and Laack, Nadia N.

Published
2022
Full Text
View/download PDF

26. Radiotherapy and Systemic Treatment for Leptomeningeal Disease.

Author

Frechette, Kelsey M., Breen, William G., Brown, Paul D., Sener, Ugur T., Webb, Lauren M., Routman, David M., Laack, Nadia N., Mahajan, Anita, and Lehrer, Eric J.

Subjects
PATIENT selection, IMMUNE checkpoint inhibitors, STEREOTACTIC radiosurgery, THERAPEUTICS, RADIOTHERAPY
Abstract

Leptomeningeal disease (LMD) is a devastating sequelae of metastatic spread that affects approximately 5% of cancer patients. The incidence of LMD is increasing due to advancements in systemic therapy and enhanced detection methods. The purpose of this review is to provide a detailed overview of the evidence in the detection, prognostication, and treatment of LMD. A comprehensive literature search of PUBMED was conducted to identify articles reporting on LMD including existing data and ongoing clinical trials. We found a wide array of treatment options available for LMD including chemotherapy, targeted agents, and immunotherapy as well as several choices for radiotherapy including whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), and craniospinal irradiation (CSI). Despite treatment, the prognosis for patients with LMD is dismal, typically 2–4 months on average. Novel therapies and combination approaches are actively under investigation with the aim of improving outcomes and quality of life for patients with LMD. Recent prospective data on the use of proton CSI for patients with LMD have demonstrated its potential survival benefit with follow-up investigations underway. There is a need for validated metrics to predict prognosis and improve patient selection for patients with LMD in order to optimize treatment approaches. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424

Author

Fisher, Barbara J., Pugh, Stephanie L., Macdonald, David R., Chakravatri, Arnab, Lesser, Glenn J., Fox, Sherry, Rogers, C. Leland, Werner-Wasik, Maria, Doyle, Thomas, Bahary, Jean-Paul, Fiveash, John B., Bovi, Joseph A., Howard, Steven P., Michael Yu, Hsiang-Hsuan, D’Souza, David, Laack, Nadia N., Barani, Igor J., Kwok, Young, Wahl, Daniel R., Strasser, Jon F., Won, Minhee, and Mehta, Minesh P.

Published
2020
Full Text
View/download PDF

29. Electrocardiogram-Gated Computed Tomography with Coronary Angiography for Cardiac Substructure Delineation and Sparing in Patients with Mediastinal Lymphomas Treated with Radiation Therapy

Author

Lester, Scott C., Taparra, Kekoa, Petersen, Molly M., Funk, Ryan K., Blanchard, Miran J., Young, Phillip M., Herrmann, Joerg, Hunzeker, Ashley E., Schultz, Heather L., McCollough, Cynthia, Tasson, Alexandria M., Leng, Shuai, Martenson, James A., Deisher, Amanda J., Whitaker, Thomas J., Williamson, Eric E., and Laack, Nadia N.

Published
2020
Full Text
View/download PDF

30. Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3)

Author

Trifiletti, Daniel M., Ballman, Karla V., Brown, Paul D., Anderson, S. Keith, Carrero, Xiomara W., Cerhan, Jane H., Whitton, Anthony C., Greenspoon, Jeffrey, Parney, Ian F., Laack, Nadia N., Ashman, Jonathan B., Bahary, Jean-Paul, Hadjipanayis, Costas G., Urbanic, James J., Barker, Fred G., II, Farace, Elana, Khuntia, Deepak, Giannini, Caterina, Buckner, Jan C., Galanis, Evanthia, and Roberge, David

Published
2020
Full Text
View/download PDF

33. Proton versus photon craniospinal irradiation for adult medulloblastoma: A dosimetric, toxicity, and exploratory cost analysis

Author

Breen, William G, primary, Geno, Connie S, additional, Waddle, Mark R, additional, Qian, Jing, additional, Harmsen, William S, additional, Burns, Terry C, additional, Sener, Ugur T, additional, Ruff, Michael W, additional, Neth, Bryan J, additional, Uhm, Joon H, additional, Routman, David M, additional, Yan, Elizabeth, additional, Kruse, Jon J, additional, Laack, Nadia N, additional, Brown, Paul D, additional, and Mahajan, Anita, additional

Published
2024
Full Text
View/download PDF

34. Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children’s Oncology Group

Author

Daw, Najat C, Laack, Nadia N, McIlvaine, Elizabeth J, Krailo, Mark, Womer, Richard B, Granowetter, Linda, Grier, Holcombe E, Marina, Neyssa M, Bernstein, Mark L, Gebhardt, Mark C, Marcus, Karen J, Advani, Shailesh M, Healey, John H, Letson, George D, Gorlick, Richard G, and Randall, R Lor

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prevention, Cancer, Pediatric Cancer, Clinical Research, Pediatric, Rare Diseases, 6.4 Surgery, Evaluation of treatments and therapeutic interventions, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Chemotherapy, Adjuvant, Child, Child, Preschool, Disease Progression, Disease-Free Survival, Female, Femur, Humans, Infant, Male, Neoplasm Metastasis, Radiotherapy, Adjuvant, Sarcoma, Ewing, Survival Rate, Tumor Burden, Young Adult, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundThe choice of a local control (LC) modality for Ewing sarcoma (EWS) of the femur is controversial. This study aimed to determine the effect of LC modality on tumor LC and patient outcomes.MethodsThe study reviewed the treatment and outcomes for 115 patients who had EWS of the femur treated with similar chemotherapy in three cooperative group trials. Patient outcomes were analyzed according to the LC modality using the log-rank test and the cumulative incidence of local or distant failure using competing risks regression.ResultsThe median age of the patients was 13 years. The most common tumor location was the proximal femur followed by the mid femur. For 55 patients with available data, the tumor was larger than 8 cm in 29 patients and 8 cm or smaller in 26 patients. For 84 patients (73 %), surgery only was performed, whereas 17 patients (15 %) had surgery plus radiation, and 14 patients (12 %) had radiation only. The 5-year event-free survival (EFS) rate was 65 % (95 % confidence interval [CI], 55-73 %), and the 5-year overall survival (OS) rate was 70 % (95 % CI, 61-78 %). Patient outcomes did not differ significantly according to tumor location within the femur (proximal, mid or distal) or tumor size (

Published
2016

35. Impact of Apolipoprotein E Genotype on Neurocognitive Function in Patients With Brain Metastases: An Analysis of NRG Oncology's RTOG 0614

Author

Wefel, Jeffrey S., primary, Deshmukh, Snehal, additional, Brown, Paul D., additional, Grosshans, David R., additional, Sulman, Erik P., additional, Cerhan, Jane H., additional, Mehta, Minesh P., additional, Khuntia, Deepak, additional, Shi, Wenyin, additional, Mishra, Mark V., additional, Suh, John H., additional, Laack, Nadia N., additional, Chen, Yuhchyau, additional, Curtis, Amarinthia (Amy), additional, Laba, Joanna M., additional, Elsayed, Ahmed, additional, Thakrar, Anu, additional, Pugh, Stephanie L., additional, and Bruner, Deborah W., additional

Published
2023
Full Text
View/download PDF

41. Patterns of proton therapy use in pediatric cancer management in 2016: An international survey

Author

Journy, Neige, Indelicato, Daniel J., Withrow, Diana R., Akimoto, Tetsuo, Alapetite, Claire, Araya, Masayuki, Chang, Andrew, Chang, John Han-Chih, Chon, Brian, Confer, Michael E., Demizu, Yusuke, Dendale, Rémi, Doyen, Jérôme, Ermoian, Ralph, Gurtner, Kristin, Hill-Kayser, Christine, Iwata, Hiromitsu, Kim, Joo-Young, Kwok, Young, Laack, Nadia N., Lee, Choonsik, Lim, Do Hoon, Loredo, Lilia, Mangona, Victor S., Mansur, David B., Murakami, Masao, Murayama, Shigeyuki, Ogino, Takashi, Ondrová, Barbora, Parikh, Rahul R., Paulino, Arnold C., Perkins, Stephanie, Ramakrishna, Naren R., Richter, Ronald, Rombi, Barbara, Shibata, Satoshi, Shimizu, Shinichi, Timmermann, Beate, Vern-Gross, Tamara, Wang, Chiachien J., Weber, Damien C., Wilkinson, John Ben, Witt Nyström, Petra, Yock, Torunn I., Kleinerman, Ruth A., and Berrington de Gonzalez, Amy

Published
2019
Full Text
View/download PDF

44. Immunohistochemical markers predicting recurrence following resection and radiotherapy in chordoma patients: insights from a multicenter study [RETRACTED]

Author

Bon Nieves, Antonio, primary, Ghaith, Abdul Karim, additional, El-Hajj, Victor Gabriel, additional, Akinduro, Oluwaseun O., additional, Ibrahim, Sufyan, additional, Ghanem, Marc, additional, Goyal, Anshit, additional, Otamendi-Lopez, Andrea, additional, Nathani, Karim Rizwan, additional, Choby, Garret, additional, Laack, Nadia N., additional, Link, Michael J., additional, Peris Celda, Maria, additional, Van Gompel, Jamie J., additional, Quiñones-Hinojosa, Alfredo, additional, Bydon, Mohamad, additional, and Pinheiro Neto, Carlos, additional

Published
2023
Full Text
View/download PDF

45. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma

Author

Sener, Ugur, primary, Webb, Mason, additional, Breen, William G., additional, Neth, Bryan J., additional, Laack, Nadia N., additional, Routman, David, additional, Brown, Paul D., additional, Mahajan, Anita, additional, Frechette, Kelsey, additional, Dudek, Arkadiusz Z., additional, Markovic, Svetomir N., additional, Block, Matthew S., additional, McWilliams, Robert R., additional, Dimou, Anastasios, additional, Kottschade, Lisa A., additional, Montane, Heather N., additional, Kizilbash, Sani H., additional, and Campian, Jian L., additional

Published
2023
Full Text
View/download PDF

46. Detection of Early Myocardial Dysfunction by Imaging Biomarkers in Cancer Patients Undergoing Photon Beam vs. Proton Beam Radiotherapy: A Prospective Study

Author

Abbasi, Muhannad Aboud, primary, Bruno, Giulia, additional, Di Stefano, Cristina, additional, Garcia Bello, Laura, additional, Laack, Nadia N., additional, Corbin, Kimberly S., additional, Whitaker, Thomas J., additional, Pellikka, Patricia A., additional, Mutter, Robert W., additional, and Villarraga, Hector R., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results